BR9913564A - Tratamento de angiopatias microvasculares - Google Patents

Tratamento de angiopatias microvasculares

Info

Publication number
BR9913564A
BR9913564A BR9913564-7A BR9913564A BR9913564A BR 9913564 A BR9913564 A BR 9913564A BR 9913564 A BR9913564 A BR 9913564A BR 9913564 A BR9913564 A BR 9913564A
Authority
BR
Brazil
Prior art keywords
treatment
methods
angiopathies
microvascular
compositions
Prior art date
Application number
BR9913564-7A
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Publication of BR9913564A publication Critical patent/BR9913564A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE ANGIOPATIAS MICROVASCULARES" A invenção refere-se à prevenção e ao tratamento de lesão endotelial e lesão dos tecidos contendo vasos sang³íneos lesionados, mediante administração de fatores angiogênicos, tal como o fator de crescimento celular endotelial vascular (VEGF).
BR9913564-7A 1998-09-09 1999-09-09 Tratamento de angiopatias microvasculares BR9913564A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
PCT/US1999/020480 WO2000013702A2 (en) 1998-09-09 1999-09-09 Use of an angiogenic factor for the treatment of microvascular angiopathies

Publications (1)

Publication Number Publication Date
BR9913564A true BR9913564A (pt) 2001-05-22

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9913533-7A BR9913533A (pt) 1998-09-09 1999-09-09 Processos para tratar hipertensão e composições para uso nos mesmos
BR9913564-7A BR9913564A (pt) 1998-09-09 1999-09-09 Tratamento de angiopatias microvasculares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9913533-7A BR9913533A (pt) 1998-09-09 1999-09-09 Processos para tratar hipertensão e composições para uso nos mesmos

Country Status (13)

Country Link
US (3) US6352975B1 (pt)
EP (2) EP1109571B1 (pt)
JP (2) JP2002532382A (pt)
AT (2) ATE260675T1 (pt)
AU (2) AU5910599A (pt)
BR (2) BR9913533A (pt)
CA (2) CA2340728C (pt)
DE (2) DE69915310T2 (pt)
DK (2) DK1112083T3 (pt)
ES (2) ES2216630T3 (pt)
IL (2) IL141687A0 (pt)
PT (2) PT1109571E (pt)
WO (2) WO2000013702A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
CA2385665A1 (en) * 1999-11-02 2001-05-10 Genentech, Inc. Modulation of enos activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE462006T1 (de) 2001-08-01 2010-04-15 Univ Bristol Isoform des vegfs
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
KR20080041145A (ko) * 2005-04-12 2008-05-09 인트라디그엠 코오포레이션 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP5158779B2 (ja) * 2005-08-31 2013-03-06 国立大学法人 香川大学 Ｄ−アロースを有効成分とする血圧上昇抑制剤
MX2011005912A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ATE152626T1 (de) 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
CA2270286C (en) * 1996-11-01 2009-03-03 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.

Also Published As

Publication number Publication date
JP2002532382A (ja) 2002-10-02
DE69915310D1 (de) 2004-04-08
IL141687A0 (en) 2002-03-10
WO2000013703A3 (en) 2000-07-06
PT1109571E (pt) 2004-05-31
WO2000013703A2 (en) 2000-03-16
DE69912815T2 (de) 2004-10-21
DE69915310T2 (de) 2005-03-10
EP1109571A2 (en) 2001-06-27
EP1112083A2 (en) 2001-07-04
US6352975B1 (en) 2002-03-05
ATE260675T1 (de) 2004-03-15
IL141686A0 (en) 2002-03-10
CA2340320A1 (en) 2000-03-16
DE69912815D1 (de) 2003-12-18
US20040224885A1 (en) 2004-11-11
ES2211165T3 (es) 2004-07-01
US20020193288A1 (en) 2002-12-19
EP1109571B1 (en) 2004-03-03
WO2000013702A3 (en) 2000-09-08
PT1112083E (pt) 2004-03-31
JP2002524421A (ja) 2002-08-06
WO2000013702A9 (en) 2000-10-19
DK1112083T3 (da) 2004-03-08
AU6028599A (en) 2000-03-27
CA2340728A1 (en) 2000-03-16
CA2340728C (en) 2007-11-27
CA2340320C (en) 2006-11-14
WO2000013702A2 (en) 2000-03-16
BR9913533A (pt) 2001-06-05
ATE253934T1 (de) 2003-11-15
EP1112083B1 (en) 2003-11-12
DK1109571T3 (da) 2004-06-21
WO2000013703A9 (en) 2000-06-02
ES2216630T3 (es) 2004-10-16
AU5910599A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
BR9913564A (pt) Tratamento de angiopatias microvasculares
PL328858A1 (en) Immunogenous peptides
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DK1303294T3 (da) Fremgangsmåde til behandling af instabil angina pectoris
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]